- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03754322
LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial (LAMPREG)
"LAMPREG TRIAL" Active Case Detection and Treatment of Malaria in Pregnancy Using LAMP Technology: A Pragmatic Randomized Multi-Center Diagnostic Outcomes Trial
Objective: The aim of this study is to evaluate the impact of enhanced malaria cases detection using molecular testing (LAMP) on maternal and infant morbidity and mortality in a prospective study design.
A pragmatic randomized control diagnostic trial will be conducted from October 2020 until March 1 2022 in pregnant mothers at sites in Ethiopia. Both symptomatic and asymptomatic first and early second trimester pregnant women will be included in the study and individually randomized to either standard of care or enhanced cased detection arms using LAMP for malaria. Women (n=2583) will be enrolled during a seven-month period encompassing the peak transmission seasons and then followed until delivery. In the standard of care arm, venous blood sample will be collected from each study participant and the presence of Plasmodium infection will be diagnosed by microscopy in symptomatic patients. Pregnant women who test positive for malaria will be referred and treated for malaria with quinine or artemisinin combination therapies (ACTs) as per national guidelines. In the intervention arm, mothers who are symptomatic or asymptomatic will be tested by a commercially available CE-approved LAMP malaria test and microscopy/RDT for malaria at each clinic visit and treated if positive by any test. Pregnant mothers who require treatment will be referred and treated with either quinine or artemisinin combination therapy (ACTs) as per national guidelines. The primary outcome is the proportion of deliveries with low birth weight based on WHO definition, with secondary outcomes of:(i)absolute birth weight; (ii) maternal hemoglobin;(ii) neonatal hemoglobin at birth;(iv) neonatal mortality; (v) stillbirth; and (vi) prematurity in each arm of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Malaria in pregnancy often results in high degree of morbidity and mortality of the pregnant mother and the fetus. Early and accurate diagnosis of subclinical infections will be critical to malaria elimination and specifically the goals of the World Health Organization to reduce the burden of disease by 90% before 2030. This goal can only be achieved using highly sensitive methods such as LAMP that are capable of detecting subclinical infections with very low parasitemia. Currently both Giemsa stained blood film microscopy and RDT are the only laboratory methods that are used to diagnose malaria both in pregnant mothers and the general population. This leaves a big gap in the detection of low-level infections and asymptomatic malaria due to the documented lack of sensitivity of the aforementioned methods. This, in turn, predisposes pregnant mothers to malaria-related complications that endangers the life of the mother and the fetus. In this study, we propose that the use of a highly sensitive LAMP technique will enable us to detect more asymptomatic Plasmodium infections in pregnant women. This consequently results in early treatment of the pregnant mothers and may avert maternal and fetal morbidity and mortality. This study is of particular importance in Ethiopia where IPT is not used for pregnant women and therefore accurate screening is paramount.
OBJECTIVES
General objective To assess the impact of LAMP in the diagnosis of malaria in pregnancy and its potential role in reducing mortality and morbidity attributable to malaria. We hypothesize that the additional sensitivity of LAMP coupled with active case detection in detecting malaria in pregnancy will result in additional cases being identified and treated.
Specific objectives
- To evaluate the impact of LAMP versus microscopy/RDT for the detection of malaria in pregnant mothers in terms maternal and infant morbidity and mortality.
- To evaluate the impact of enhanced case detection of malaria in pregnancy by screening asymptomatic mothers at each antenatal visit until delivery.
- To determine the impact of treating LAMP-positive asymptomatic and symptomatic pregnant women as compared to standard of care. Treatment is per national guidelines.
MATERIALS AND METHODS
Study area The study will be conducted at sites across several sites in Ethiopia to obtain sufficient enrolment and spanning different transmission settings based on epidemiological data provided by the Federal Ministry of Health. The study sites are in the Amhara region (Chisabay Health center, Hamusit health center and Andasa Health center), and in the Jimma area (Bonga (GebreTsadik Shawo) General hospital, Uffa health center and Lare health center). In Ethiopia, malaria is characterized by its seasonality where the peak transmission season is from October to December with a second peak in June. P. falciparum and P. vivax are the predominant species in the area.
Study design and period
The study is a prospective diagnostic study of malaria in pregnant women. The goal is to determine whether: (i) LAMP provides a clinically measurable benefit compared to current first line diagnostic test of Giemsa-stained microscopy and whether (ii) enhanced case detection of asymptomatic mothers with LAMP has added value in terms of outcomes. We hypothesize that addition of LAMP to one arm will be of greater benefit than microscopy alone due to additional LAMP sensitivity. We further hypothesize that enhanced case detection by screening asymptomatic mothers at each antenatal visit will be of additional value in treating malaria. Both symptomatic and asymptomatic first and second trimester mothers will be included in the study and individually randomized to one of two arms: standard of care or enhanced cased detection arms using LAMP for malaria. Mothers will be enrolled during a seven-month period from June 2021 to January 2022 and then followed until 28 days after delivery. Given the rate of pregnant mothers at the locations, we anticipate that the required minimum of 2583 mothers will be enrolled in the study during the study period. In the first standard of care arm, venous blood sample will be collected from each study participant and the presence of Plasmodium infection will be diagnosed by microscopy in symptomatic patients. Pregnant women who test positive for malaria will be referred and treated for malaria with quinine or ACTs as per national guidelines. In the second (test) arm, mothers whether symptomatic or asymptomatic will be tested by a commercially available CE-approved LAMP malaria test (Human Diagnostics LoopAMP (Wiesbaden, Germany)) at each clinic visit in addition to RDT/microscopy. The commercial LAMP tests can distinguish P. falciparum and P. vivax and treatment will be given according to national guidelines. The purpose of doing all tests in the intervention arm is to determine how many additional cases LAMP identified. The primary outcome is the proportion of deliveries with low birth weight, with secondary outcomes of: (i) absolute birth weight; (ii) maternal hemoglobin; (ii) neonatal hemoglobin at birth (Standard Hgb testing from peripheral blood or finger prick); (iv) neonatal mortality; (v) pregnancy loss; and (vi) prematurity in each of the two arms.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dylan Pillai, MD, PhD
- Phone Number: 403-770-3578
- Email: drpillai@ucalgary.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2L 2K8
- Active, not recruiting
- University of Calgary
-
-
-
-
-
Addis Ababa, Ethiopia
- Not yet recruiting
- Armauer Hansen Research Institute, Ethiopia
-
Contact:
- Mekonnen Teferi, PhD
- Phone Number: 251-13483752
- Email: mekonnen.teferi@ahri.gov.et
-
-
Amhara
-
Bahir Dar, Amhara, Ethiopia
- Recruiting
- Amhara Public Health Institute
-
Contact:
- Banchamlak Tegegne, MSc
- Phone Number: +251582201698
- Email: banteg92@gmail.com
-
-
Oromia
-
Jimma, Oromia, Ethiopia
- Active, not recruiting
- Tropical & Infectious Diseases Research Center (TIDRC), Jimma University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must be a pregnant woman in the first or second trimester at time of enrollment
- Consent to the study
Exclusion Criteria:
- Pregnant woman in the third trimester at time of enrollment
- Multiparity
- Severe malaria at inclusion as per WHO criteria
- At risk pregnancy as per Ethiopian guidelines
- Impossibility to date pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of care
One third of individuals get allocated to the standard of care arm.
At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy.
If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium.
If it is negative they receive no treatment.
If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
|
Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
|
Experimental: Intervention arm
The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT).
If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines.
If both are negative then they receive no treatment.
|
Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of deliveries with low birth weight
Time Frame: At the head to toe assessment of the baby within 24 hours of delivery
|
Birth weight will be considered as low if < 2500 g
|
At the head to toe assessment of the baby within 24 hours of delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute birth weight
Time Frame: At the head to toe assessment of the baby within 24 hours of delivery
|
Birth weight in grams
|
At the head to toe assessment of the baby within 24 hours of delivery
|
Maternal hemoglobin
Time Frame: During the pregnancy and at delivery
|
Maternal hemoglobin in g/dL
|
During the pregnancy and at delivery
|
Neonatal hemoglobin at birth
Time Frame: At the head to toe assessment of the baby within 24 hours of delivery
|
Foetal hemoglobin in g/dL
|
At the head to toe assessment of the baby within 24 hours of delivery
|
Proportion of fetal loss
Time Frame: During the study time, for each inclusion until delivery
|
Early stillbirth < 20-27 completed weeks of pregnancy Late stillbirth 28 -36 weeks of pregnancy Term still birth > 37 weeks of pregnancy
|
During the study time, for each inclusion until delivery
|
Prematurity
Time Frame: At delivery
|
Baby born Extremely preterm < 28 weeks of pregnancy Very preterm 28-32 weeks of pregnancy Moderate to late preterm 32-37 weeks of pregnancy
|
At delivery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance of diagnosis methods compared to qRT-PCR as a gold standard
Time Frame: At the end of the study
|
Evaluation of the sensitivity, specificity, PPV and NPV for LAMP, RDT and microscopy in the study
|
At the end of the study
|
Assessment of the development of placental malaria
Time Frame: At delivery and post hoc
|
Evaluation of the presence of malaria pigment in macrophages from placental blood.
qPCR in placenta blood
|
At delivery and post hoc
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dylan Pillai, MD, PhD, University of Calgary
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB17-1335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Microscopy/RDT
-
Universidad Nacional de ColombiaCompleted
-
Foundation for Innovative New Diagnostics, SwitzerlandBurnet Institute; Papua New Guinea Institute of Medical ResearchUnknownDiagnoses Disease | Plasmodium Falciparum Malaria | Pregnancy Malaria
-
Foundation for Innovative New Diagnostics, SwitzerlandUniversidad de AntioquiaCompletedDiagnoses Disease | Plasmodium Falciparum | Pregnancy MalariaColombia
-
University Research Co, LLCDuke University; United States Agency for International Development (USAID); Centers... and other collaboratorsUnknownMalaria,Falciparum | Malaria DiagnosisMyanmar
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedPneumonia | Fever | Malaria | Acute Febrile IllnessAfghanistan
-
Ghana Health ServicesLondon School of Hygiene and Tropical MedicineCompleted
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
Assiut UniversityNot yet recruiting
-
PATHNot yet recruitingPrimary Immunodeficiency DiseasesPakistan
-
PATHCentro de Pesquisa em Medicina Tropical de RondoniaRecruiting